ArticleAdvanced materials (Deerfield Beach, Fla.)2026
Autonomous Hydrogel Actuators Programmed by Endogenous Biochemical Logic for Dual-Stage Morphing and Drug Release.
Article in Advanced materials (Deerfield Beach, Fla.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Designing soft materials that autonomously respond to complex physiological environments remains a fundamental challenge in biomedical systems engineering. Here, we report on a 3D-printed hybrid protein-polymer hydrogel actuator that operates via endogenous biochemical logic, enabling fully autonomous dual-stage shape morphing and enzyme-triggered drug release in gastric-mimicking environments. The actuator comprises a bilayer structure: an active layer based on bovine serum albumin-poly (ethylene glycol) diacrylate (BSA-PEGDA), and a passive PEGDA layer. In acidic gastric fluid, the BSA-PEGDA layer undergoes rapid conformational swelling, followed by delayed softening from pepsin-mediated degradation, autonomously driving reversible shape transitions without manual intervention. By embedding doxorubicin (DOX) within the BSA-PEGDA hydrogel network, the system achieves site-specific, enzyme-gated drug release that is tunable using pepstatin A as a biochemical inhibitor. High-resolution digital light processing (DLP) printing enables the fabrication of complex autonomous actuators and microneedle-equipped grippers capable of mucosal adhesion, catch-and-release behavior, and controlled delivery. This work establishes a materials design strategy where biochemical cues are used as programmable inputs to drive mechanical and therapeutic outputs, offering a robust platform for bioresponsive soft robotics and in situ drug delivery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.